[어바웃C] 제일약품, 부소장직 신설…대웅제약 출신 박준석 영입

Jeil Pharmaceutical's recruitment of a seasoned drug discovery leader to drive JP-2266, an SGLT2 inhibitor, underscores the company's strategic bet on capturing high-growth diabetes care with differentiated cardiovascular and renal benefits. As Phase 3 clinical trials are imminent, this executive move reflects the industry reality that experienced R&D talent is critical to accelerating development velocity and maximizing commercial success. For investors, this signals Jeil's commitment to establishing post-Jacubo growth drivers and leveraging deep pharmaceutical expertise to navigate competitive drug development cycles.